Montreal, Canada

Isabelle Lemire

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 127(Granted Patents)


Location History:

  • Montréal, CA (2010 - 2018)
  • Montreal, CA (2006 - 2022)

Company Filing History:


Years Active: 2006-2022

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Isabelle Lemire

Introduction

Isabelle Lemire is a prominent inventor based in Montreal, Canada. She has made significant contributions to the field of biomedical engineering, particularly in the development of novel methods and compositions for treating bone-related conditions. With a total of 7 patents to her name, her work has the potential to impact many lives.

Latest Patents

Among her latest patents, Lemire has developed a bone delivery conjugate designed to target proteins to bone. This conjugate features a unique structure that includes various amino acid sequences and poly aspartate components. Additionally, she has created methods for treating multiple osteochondroma (MO), which involve administering palovarotene or its pharmaceutically acceptable salts. These methods aim to inhibit the formation and growth of osteochondromas, thereby alleviating complications associated with this condition.

Career Highlights

Throughout her career, Isabelle Lemire has worked with notable companies such as Enobia Pharma Inc. and Alexion Pharmaceuticals, Inc. Her innovative approaches and dedication to research have positioned her as a leader in her field.

Collaborations

Lemire has collaborated with esteemed colleagues, including Philippe Crine and Guy Boileau. These partnerships have further enhanced her research and development efforts.

Conclusion

Isabelle Lemire's contributions to biomedical engineering and her innovative patents demonstrate her commitment to advancing medical science. Her work continues to pave the way for new treatments and improved patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…